Study breakdowns on peptides, mechanisms explained, and practical guides. What the research showed — and what nobody has measured. Educational material, not medical advice.
A comprehensive scientific review of testosterone suspension, the unesterified aqueous testosterone preparation, covering its historical significance as the original injectable testosterone, unique pharmacokinetics, immediate peak kinetics, clinical applications, and comparative pharmacology.
An extensive scientific review of testosterone undecanoate, the longest-acting injectable testosterone ester and the only oral testosterone formulation with established clinical efficacy, covering its unique pharmacokinetics, dual formulation strategies, clinical evidence, and role in modern TRT.
A comprehensive scientific review of testosterone propionate, the shortest-chain commonly used testosterone ester, examining its rapid pharmacokinetics, historical significance as the first clinically available testosterone ester, administration requirements, and clinical applications.
Testosterone enanthate is a testosterone ester (C26H40O3) forming an intramuscular oil depot with an effective half-life of 6 to 8 days. Europe's most prescribed injectable testosterone for male hypogonadism, it is dosed at 250 mg every 2 to 3 weeks or 125 mg every 1 to 2 weeks and is a Schedule III controlled substance in the United States.
A thorough scientific review of testosterone cypionate, the most widely prescribed testosterone ester in the United States, covering its chemical structure, pharmacokinetics, clinical indications, dosing protocols, side effect profile, blood level dynamics, and regulatory status.
A practical guide to LL-37 research protocols, covering peptide preparation, reconstitution, dosage considerations for antimicrobial and immunomodulatory research, administration routes, in vitro and in vivo experimental protocols, storage requirements, and safety considerations.
A comparative analysis of LL-37 versus alternative antimicrobial peptides and immune defense molecules, including defensins, melittin, nisin, Thymosin Alpha-1, and conventional antibiotics, evaluating antimicrobial spectra, immunomodulatory properties, resistance profiles, and therapeutic potential.
A thorough scientific review of LL-37, the sole human cathelicidin antimicrobial peptide, covering its discovery, structure, antimicrobial mechanisms, immunomodulatory functions, roles in innate immunity, wound healing, and cancer biology, and its therapeutic development status.
A practical research guide for Thymosin Beta-4, covering reconstitution protocols, dosage recommendations for various research applications, administration routes, cycling strategies, storage requirements, quality control, and safety monitoring for research settings.
A comparative analysis of Thymosin Beta-4 versus alternative tissue repair and regenerative peptides including BPC-157, TB-500, GHK-Cu, and growth hormone secretagogues, evaluating mechanisms, evidence quality, clinical applications, and practical considerations.
A comprehensive scientific review of Thymosin Beta-4, the 43-amino acid tissue repair and anti-inflammatory peptide, covering its discovery, actin-binding mechanism, roles in wound healing, cardiac repair, neuroprotection, and its relationship to the commercially available fragment TB-500.
A practical guide to Thymosin Alpha-1 research protocols, covering preparation, reconstitution, dosage recommendations, subcutaneous administration techniques, cycling strategies, storage conditions, safety monitoring, and contraindications for research applications.
Thymosin Alpha-1 (Ta1) is a thymic peptide that enhances immunity via dendritic cell activation and T cell maturation, without the inflammatory side effects that make 10 to 15 percent of interferon-alpha patients stop treatment. Standard regimen is 1.6 mg subcutaneously twice weekly; Zadaxin costs less than pegylated interferon or checkpoint inhibitors. Direct-acting antivirals have reduced its role in viral hepatitis.
A thorough scientific review of Thymosin Alpha-1, the thymic peptide immune modulator marketed as Zadaxin, covering its discovery, molecular structure, immunological mechanisms, clinical evidence in viral hepatitis, cancer immunotherapy, and immunodeficiency, and its regulatory status worldwide.
A practical guide to liraglutide covering formulations, dose-escalation protocols for both diabetes and obesity indications, daily injection technique, comprehensive side effect management, storage and handling, monitoring requirements, and considerations for transitioning to newer agents.
A comprehensive comparison of liraglutide with semaglutide and tirzepatide, examining how this pioneering GLP-1 receptor agonist measures against newer-generation incretin therapies across efficacy, cardiovascular outcomes, safety, convenience, and clinical positioning.
A thorough scientific review of liraglutide, the pioneering GLP-1 receptor agonist marketed as Victoza and Saxenda, covering its development history, molecular structure, mechanism of action, comprehensive clinical trial evidence for diabetes and obesity, cardiovascular outcomes, and its role as the foundation of modern incretin-based therapy.
Tirzepatide is sold as Mounjaro and Zepbound in prefilled pens for once-weekly subcutaneous injection. Dosing escalates from 2.5 mg to 15 mg in four-week steps, with 5, 10 and 15 mg as maintenance doses. Gastrointestinal effects dominate tolerability — nausea reached 12-33% in trials — and the drug is contraindicated in pregnancy and not combined with other GLP-1 receptor agonists.
A detailed comparative analysis of tirzepatide against semaglutide and liraglutide, focusing on the advantages and limitations of dual GIP/GLP-1 receptor agonism versus selective GLP-1 receptor agonism across efficacy, safety, and practical dimensions.
A detailed scientific review of tirzepatide, the first-in-class dual GIP/GLP-1 receptor agonist marketed as Mounjaro and Zepbound, examining its novel mechanism, molecular design, comprehensive clinical trial data, and its position as the most potent weight loss medication currently available.
A practical guide covering semaglutide formulations, dose-escalation schedules, injection technique, side effect management strategies, storage requirements, and monitoring protocols for research and clinical settings.
A comprehensive comparison of semaglutide with tirzepatide and liraglutide, examining differences in receptor pharmacology, weight loss efficacy, glycemic control, cardiovascular outcomes, dosing convenience, side effect profiles, and cost considerations.
A thorough scientific review of semaglutide, the GLP-1 receptor agonist marketed as Ozempic and Wegovy, covering its discovery, molecular structure, mechanism of action, landmark clinical trial results for type 2 diabetes and obesity, cardiovascular benefits, and regulatory history.
TB-500 is a synthetic fragment of Thymosin Beta-4 that binds actin monomers, so it is dosed in milligrams rather than micrograms: 4 to 8 milligrams per week for 4 to 6 weeks, then 2 to 4 milligrams per week, by subcutaneous or intramuscular injection. Preclinical safety is favorable, but its unresolved relationship to tumor biology excludes subjects with active cancer.
A detailed comparative analysis of TB-500 against BPC-157, GHK-Cu, MGF, and other tissue repair peptides, evaluating their distinct mechanisms, evidence quality, tissue specificity, practical considerations, and potential for synergistic combination protocols in regenerative research.
A comprehensive scientific review of TB-500, a synthetic fragment of Thymosin Beta-4, covering its origin from thymic tissue research, molecular structure and actin-binding properties, mechanisms of tissue repair including cell migration and anti-inflammatory signaling, preclinical and clinical evidence, and current regulatory landscape.
A practical guide for BPC-157 research covering reconstitution protocols, dosage calculations for various administration routes including oral and injectable, cycling strategies, stability and storage requirements, and comprehensive safety considerations based on published literature.
A comprehensive comparative analysis of BPC-157 against TB-500, GHK-Cu, and other healing peptides, examining their distinct mechanisms of action, tissue specificity, evidence base, administration routes, and potential synergistic applications in tissue repair research.
BPC-157 is a 15-amino-acid fragment of a protective protein from gastric juice, stable there for at least 24 hours, with hundreds of published preclinical studies spanning gut, tendon, nerve, liver and heart injury. Human data remain scarce: no completed phase III trial exists, the FDA has not approved it and restricted compounding in 2022, and WADA prohibits it.
A practical guide to MK-677 (ibutamoren) research covering oral dosing protocols, timing optimization, metabolic monitoring requirements, body composition assessment strategies, sleep study methodology, long-term protocol design, and management of common side effects.
MK-677 is the only oral, non-peptide GH secretagogue with extensive clinical trial data. At 25 mg daily it lifts IGF-1 by 40 to 60 percent, versus 15 to 30 percent for injected GHRP-2, with no tachyphylaxis over 24 months. The trade-off is metabolic: fasting glucose rises 5 to 15 mg per deciliter and appetite stays elevated.
MK-677 (ibutamoren) is an orally active, non-peptide ghrelin mimetic that stimulates pulsatile growth hormone release through the GHS-R1a receptor. At 25 mg daily it raised mean 24-hour GH by 97% and IGF-1 by roughly 40 to 50% in elderly subjects; increased appetite affects 40 to 60% and insulin sensitivity falls. It is unapproved by the FDA and EMA and WADA-prohibited.
A practical guide to hexarelin research covering reconstitution, dosing for GH stimulation and cardiovascular applications, strategies for managing tachyphylaxis, combination protocols, cardiovascular endpoint measurements, and monitoring considerations.
A detailed comparative analysis of hexarelin against other growth hormone secretagogues, examining its unique CD36 receptor activity, superior acute GH potency versus tachyphylaxis limitations, cardiovascular advantages, and positioning relative to GHRP-2, GHRP-6, ipamorelin, and MK-677.
A comprehensive scientific review of hexarelin, the most potent synthetic hexapeptide growth hormone secretagogue, covering its molecular structure, receptor pharmacology, GH-releasing capacity, pronounced cardiovascular effects, neuroendocrine profile, tachyphylaxis characteristics, and clinical development history.
A practical guide to GHRP-6 research covering reconstitution, dosing strategies, appetite management, combination protocols, gastroprotective applications, monitoring parameters, and troubleshooting for common issues in GHRP-6 research.
A comprehensive comparative analysis of GHRP-6 against other GH secretagogues and related peptides, evaluating differences in GH potency, appetite effects, tissue-protective properties, hormonal side effects, and clinical applicability across research contexts.
A comprehensive scientific review of Growth Hormone Releasing Peptide-6 (GHRP-6), one of the earliest synthetic ghrelin mimetics, covering its discovery, hexapeptide structure, GH secretion mechanisms, pronounced appetite stimulation, gastroprotective properties, cardioprotective effects, and clinical research history.
A practical guide to GHRP-2 in research settings, covering reconstitution procedures, dosing protocols, injection techniques, timing strategies, combination approaches with GHRH analogs, monitoring parameters, and storage requirements.
A detailed comparative analysis of GHRP-2 against other growth hormone secretagogues including GHRP-6, hexarelin, ipamorelin, and MK-677, examining differences in GH release potency, side effect profiles, receptor selectivity, and suitability for various research applications.
A thorough scientific review of Growth Hormone Releasing Peptide-2 (GHRP-2), covering its molecular structure, ghrelin receptor agonism, GH secretion kinetics, neuroendocrine effects, metabolic actions, and the extensive body of preclinical and clinical research establishing its pharmacological profile.
A practical guide to sermorelin research and clinical use covering reconstitution procedures, dosing protocols from clinical trials and compounding pharmacy practice, administration timing, combination strategies, storage requirements, and comprehensive safety monitoring.
A comparative analysis of sermorelin against CJC-1295, tesamorelin, exogenous growth hormone, and GH secretagogues, evaluating their mechanisms, regulatory status, clinical evidence, safety profiles, and practical advantages for research and clinical applications.
A thorough scientific review of sermorelin (GHRH(1-29) analog), covering its discovery as the minimal bioactive GHRH fragment, FDA approval history, mechanism of action through the GHRH receptor, clinical evidence in growth hormone deficiency and aging, and current regulatory and therapeutic landscape.
CJC-1295 is a GHRH analog supplied in two forms with different dosing: without DAC (Mod GRF 1-29) at 100 to 200 mcg per injection 1 to 3 times daily, often combined with Ipamorelin; with DAC, whose 6 to 8-day half-life allows 2 mg once weekly. Monitoring covers IGF-1, glucose and thyroid function; side effects are mostly mild flushing and headache.
A comparative analysis of CJC-1295 against other GHRH analogs and GH-stimulating compounds including sermorelin, tesamorelin, and direct GH secretagogues, evaluating their mechanisms, pharmacokinetics, efficacy, and practical research applications.
A comprehensive scientific review of CJC-1295, the synthetic GHRH analog peptide, covering the distinction between CJC-1295 with and without DAC, its molecular structure, mechanism of action through the GHRH receptor, clinical trial evidence, pharmacokinetics, and regulatory status.
Ipamorelin is a selective GH secretagogue; Novo Nordisk trials set effective doses near 1 mcg/kg; research protocols typically use 200 to 300 mcg subcutaneously 2 to 3 times daily, fasted. It appears more desensitization-resistant than other GHS compounds, side effects are generally mild, but continuous dosing beyond 12 weeks is little documented and active malignancy remains a contraindication.
Among growth hormone secretagogues, Ipamorelin releases GH without cortisol, prolactin or appetite stimulation. At 1 mcg/kg it produces peaks of roughly 20 to 40 ng/mL, below hexarelin's 40 to 80 ng/mL, but its response holds up with repeated dosing while hexarelin desensitizes. None of these compounds, including oral MK-677, is approved for GH stimulation; all are WADA-prohibited.
A thorough scientific review of Ipamorelin, the highly selective growth hormone secretagogue pentapeptide, covering its discovery, molecular structure, ghrelin-mimetic mechanism, clinical evidence from human trials, and current regulatory landscape.
A practical guide to Dihexa for laboratory research, covering handling of this potent compound, solution preparation for in vitro and in vivo studies, published dosing protocols from animal research, and critical safety considerations.
Dihexa is a small-molecule cognitive enhancer acting through HGF/c-Met signaling to promote new synapse formation, unlike BDNF-based agents such as Semax and Noopept or cholinesterase inhibitors like donepezil. In comparable assays it drives synaptogenesis at concentrations approximately 10 million-fold lower than BDNF. Its evidence is exclusively preclinical: no human safety data exist, and c-Met is a known proto-oncogene.
A comprehensive review of Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide), the extraordinarily potent angiotensin IV analog, covering its hepatocyte growth factor receptor mechanism, cognitive enhancement properties, and potential for neurodegenerative disease treatment.
A practical guide to Cortexin research covering intramuscular administration protocols, dosing regimens for adults and children, treatment course design, storage requirements, and safety considerations.
A comparative analysis of Cortexin versus Cerebrolysin and synthetic neuropeptides, examining their composition, clinical evidence, practical considerations, and the trade-offs between complex biological extracts and defined synthetic compounds.
An in-depth review of Cortexin, the polypeptide complex derived from bovine/porcine brain cortex, covering its composition, neuroprotective mechanisms, Russian clinical evidence in stroke and neurodevelopmental disorders, and relationship to Pinealon.
A practical guide to Cerebrolysin research covering intravenous and intramuscular administration protocols, dosing regimens from clinical trials, treatment course design, storage requirements, and safety monitoring.
Cerebrolysin, a porcine brain-derived mixture of thousands of peptides, engages neurotrophic, anti-inflammatory and neuroplastic pathways, and its cognitive benefits persist for months after treatment, unlike cholinesterase inhibitors. Against Semax and Noopept it offers the strongest clinical trial database but requires daily intravenous infusions of 10 to 30 ml for 10 to 20 days and carries a seizure risk in epilepsy.
Cerebrolysin is a porcine brain-derived mixture of neuropeptides and amino acids that mimics endogenous neurotrophic factors. Over 200 clinical studies cover more than 50,000 patients; in the 1,070-patient CASTA stroke trial the primary endpoint missed significance, with benefit seen in severe strokes. Approved in over 50 countries but not by the FDA, it is contraindicated in epilepsy.
A practical guide to Noopept research covering oral, sublingual, and intranasal administration, dosing protocols from clinical trials, cycling strategies, storage requirements, and safety considerations.
Noopept is a small-molecule nootropic that modulates AMPA glutamate receptors and upregulates BDNF and NGF. It works at 10 to 30 mg per day, a 100 to 200 fold lower dose than piracetam's 1200 to 4800 mg, with acute effects within 15 to 20 minutes of oral dosing. Unlike Semax it is orally bioavailable; evidence for combinations remains anecdotal.
A comprehensive review of Noopept (N-phenylacetyl-L-prolylglycine ethyl ester), the potent dipeptide nootropic developed in Russia, covering its unique mechanism combining neurotrophic factor modulation with glutamatergic enhancement, clinical evidence, and cognitive effects.
Selank is sold in Russia as a 0.15 percent intranasal solution (1.5 mg per ml) and elsewhere as lyophilized powder in 5 mg or 10 mg vials. Clinical trials studied 450 micrograms per day, typically three 150 microgram sprays, in 14 to 21 day courses then 1 to 4 weeks of rest. No sedation, tolerance, or withdrawal has been reported.
A comparative analysis of Selank versus benzodiazepines, Semax, and other anxiolytic agents, examining mechanisms, anxiolytic efficacy, cognitive effects, and safety profiles for anxiety and stress research.
An in-depth review of Selank, the synthetic heptapeptide anxiolytic derived from tuftsin, covering its molecular design, GABAergic mechanisms, clinical research in anxiety disorders, immunomodulatory properties, and cognitive enhancement effects.
Semax is an ACTH-derived peptide taken mainly intranasally, sold in Russia as 0.1 percent and 1 percent nasal solutions. Nootropic protocols use 200 to 600 micrograms per day in 10 to 14 day courses, while acute stroke trials used 12 mg per day. Two decades of Russian clinical use report mild side effects; pregnancy and nasal infections are contraindications.
A comparative analysis of Semax versus Selank, Noopept, and other cognitive-enhancing peptides, examining mechanisms of action, clinical evidence, efficacy profiles, and practical considerations for neuroprotection research.
A thorough review of Semax, the synthetic heptapeptide analog of ACTH(4-10) developed in Russia, covering its molecular structure, neurotrophic mechanisms, clinical applications in stroke and cognitive enhancement, and regulatory landscape.
A practical guide to Pinealon research covering available formulations, dosing protocols from published literature, administration routes, cycling strategies, storage conditions, and safety considerations.
A detailed comparison of Pinealon with DSIP and other sleep-recovery peptides, evaluating their respective mechanisms, clinical evidence, practical considerations, and potential synergistic applications in sleep and neuroprotection research.
An in-depth review of Pinealon (Glu-Asp-Arg), the synthetic tripeptide bioregulator developed from Russian gerontology research, examining its epigenetic mechanisms, neuroprotective properties, circadian regulation effects, and clinical research findings.
A practical guide to DSIP research covering reconstitution protocols, dosage ranges from clinical literature, administration timing, cycling strategies, storage requirements, and safety considerations for laboratory use.
A comparative analysis of Delta Sleep-Inducing Peptide and alternative sleep-promoting peptides including Pinealon, examining mechanisms, efficacy profiles, and clinical evidence for each approach to sleep optimization.
A thorough review of Delta Sleep-Inducing Peptide (DSIP), covering its discovery in 1974, nonapeptide structure, multifaceted mechanisms of action, clinical research on sleep promotion and stress adaptation, and current regulatory status.
A practical guide for researchers working with PEG-MGF, covering reconstitution protocols, subcutaneous and intramuscular administration techniques, research dosing parameters, cycling considerations, and storage requirements.
PEGylation stretches MGF's half-life from 5 to 7 minutes to 24 to 72 hours, allowing subcutaneous dosing two to three times per week. Where IGF-1 LR3 is the stronger driver of protein synthesis, PEG-MGF's strength is activating satellite cells; it carries no meaningful hypoglycemia risk, though anti-PEG antibodies are a concern. Follistatin, which blocks myostatin, is potentially complementary.
A comprehensive review of PEGylated Mechano Growth Factor, examining how polyethylene glycol modification transforms the pharmacological properties of MGF and the current state of research on muscle repair and regeneration.
A practical guide for researchers working with native MGF peptide, addressing its unique stability challenges, reconstitution requirements, intramuscular administration techniques, and experimental design considerations.
A comparative analysis of native MGF against PEG-MGF and IGF-1 LR3, examining the trade-offs between localized potency and systemic bioavailability in muscle growth factor research.
A comprehensive review of Mechano Growth Factor, the IGF-1 splice variant uniquely expressed in response to mechanical muscle loading, covering its discovery, molecular biology, satellite cell activation mechanism, and research findings.
A practical guide for researchers working with IGF-1 LR3, covering reconstitution techniques, research dosing protocols, cycling parameters, storage requirements, and critical safety considerations including hypoglycemia management.
A detailed comparison of IGF-1 LR3 with MGF and PEG-MGF, examining how these three IGF-1 pathway peptides differ in their mechanisms, pharmacokinetics, and research applications for muscle growth.
An in-depth review of IGF-1 LR3, the synthetic long-acting analog of insulin-like growth factor-1, covering its structural modifications, enhanced bioavailability, mechanism of action, and research applications in muscle biology.
A practical guide for researchers working with follistatin, covering reconstitution protocols, research dosing parameters, storage requirements, stability considerations, and safety monitoring guidelines.
Follistatin promotes muscle growth by binding and neutralizing myostatin, whereas IGF-1 LR3, MGF and PEG-MGF act through the IGF-1 receptor. As a large glycoprotein it is hard to deliver, so research has shifted to adeno-associated viral gene therapy; IGF-1 LR3 carries hypoglycemia risk, while follistatin's concerns are reproductive function and bone metabolism. The pathways are independent and may be additive.
A thorough examination of follistatin, the naturally occurring glycoprotein that inhibits myostatin and activin, covering its discovery, molecular structure, isoforms, mechanism of action, and current clinical research status.
Behavioral vasopressin research relies on intranasal dosing of 20 to 40 IU, with tasks run 30 to 45 minutes after administration; intravenous doses of 0.01 to 0.03 units per kilogram serve pharmacokinetic and cardiovascular work. Vasoconstrictor and antidiuretic effects call for blood pressure and serum sodium monitoring, and pregnant women are excluded because cross-reactivity with OXTR can trigger uterine contractions.
A comparative analysis of vasopressin and oxytocin as social neuropeptides, examining their complementary roles in sexual behavior, pair bonding, and social cognition, with emphasis on sex-dependent effects, receptor cross-reactivity, and therapeutic implications.
Arginine vasopressin is a nine-amino-acid hormone synthesized by du Vigneaud in 1953 that acts through three receptors: V1a (vasoconstriction, social behavior), V1b (pituitary ACTH release) and V2 (renal water reabsorption). Prairie vole studies tied V1a receptors to male pair bonding, and intranasal doses of 20 to 40 IU alter human social cognition, though its cardiovascular effects require monitoring.
A practical guide for oxytocin research, covering intranasal and injectable formulations, dosing protocols for social and sexual behavior studies, reconstitution procedures, storage requirements, experimental design considerations, and safety monitoring parameters.
A detailed comparative analysis of oxytocin and vasopressin, two structurally related nonapeptides with distinct but overlapping roles in sexual behavior, pair bonding, social cognition, and emotional processing, examining their receptor systems, sex-dependent effects, and complementary functions.
A comprehensive scientific overview of oxytocin, the nonapeptide hormone known for its roles in bonding, sexual function, and social behavior, covering its Nobel Prize-winning synthesis, receptor pharmacology, diverse physiological roles, and expanding clinical research applications.
A practical guide for kisspeptin-10 research, covering peptide reconstitution, dosing protocols for intravenous and subcutaneous administration, experimental design considerations for reproductive hormone studies, storage requirements, and safety monitoring parameters.
A comparative analysis of kisspeptin-10 and PT-141 as sexual health peptides, examining their fundamentally different mechanisms, receptor targets, hormonal versus neurological pathways, clinical development status, and complementary roles in reproductive and sexual function research.
A detailed scientific overview of kisspeptin-10, the minimal active fragment of the KISS1 gene product, examining its critical role in GnRH regulation, reproductive hormone axis control, emerging research in sexual arousal, and therapeutic potential for reproductive disorders.
A detailed practical guide for Melanotan II research, covering reconstitution procedures, research dosing protocols for both pigmentation and sexual function studies, administration techniques, cycling approaches, storage conditions, and critical safety considerations.
A systematic comparison of Melanotan II with PT-141 (bremelanotide), examining their shared melanocortin origins but divergent pharmacological profiles, receptor selectivities, clinical development paths, and respective roles in sexual health research.
An in-depth scientific overview of Melanotan II, the cyclic alpha-MSH analog developed at the University of Arizona, examining its non-selective melanocortin receptor activity, dual effects on pigmentation and sexual function, safety profile, and regulatory status.
A comprehensive practical guide for PT-141 (bremelanotide) research, covering reconstitution protocols, research dosage ranges, administration timing, cycling strategies, storage requirements, and safety monitoring considerations.
A detailed comparison of PT-141 (bremelanotide) with Melanotan II and PDE5 inhibitors, examining their distinct mechanisms of action, efficacy profiles, side effects, and clinical applications in sexual health research.
A thorough examination of PT-141 (bremelanotide), the first melanocortin receptor agonist approved for sexual dysfunction, covering its development from Melanotan II, mechanism of action on MC4R, clinical trial outcomes, and FDA approval as Vyleesi.
A practical guide to SS-31 (elamipretide) research covering reconstitution, dosing protocols for preclinical and clinical studies, storage requirements, administration techniques, combination strategies, and safety monitoring.
SS-31 binds cardiolipin in the inner mitochondrial membrane, where it concentrates 1000 to 5000-fold, reducing superoxide production; NAD+ precursors (NMN, NR) refill the cofactor pool that fuels sirtuins and PARPs. In aged mice, SS-31 combined with NMN restores both diastolic and systolic heart function. SS-31 is injectable and in Phase 2 and 3 trials; NAD+ precursors are oral supplements.
A comprehensive review of SS-31 (elamipretide), the mitochondria-targeted tetrapeptide that binds cardiolipin to optimize electron transport chain function, reduce oxidative stress, and enhance ATP production, with clinical trials in heart failure, Barth syndrome, and mitochondrial myopathy.
A practical guide to NAD+ precursor research covering NMN and NR selection, dosing protocols, storage requirements, biomarker monitoring, combination strategies, and safety considerations for laboratory and clinical applications.
A comparative analysis of NAD+ precursors (NMN and NR) against SS-31 (elamipretide) for mitochondrial health and longevity, examining their distinct mechanisms of NAD+ biosynthesis versus cardiolipin stabilization and their potential synergy.
NMN and NR are NAD+ precursors: they raise levels of nicotinamide adenine dinucleotide, a coenzyme required by over 500 enzymatic reactions that falls by approximately 50 percent between ages 40 and 60. At 250 to 1000 mg per day both double blood NAD+ within 14 days, yet human anti-aging evidence remains preliminary and NMN's US supplement status is uncertain.
A practical guide to MOTS-c research covering reconstitution protocols, dosing strategies for metabolic and performance studies, storage requirements, administration routes, and safety monitoring recommendations.
A comparative analysis of MOTS-c against epithalon and humanin in the longevity peptide landscape, examining how AMPK-mediated metabolic optimization compares with telomerase activation and mitochondrial cytoprotection for anti-aging applications.
A comprehensive review of MOTS-c, the mitochondrial-derived exercise mimetic peptide that activates AMPK, translocates to the nucleus during metabolic stress, and demonstrates remarkable effects on metabolism, physical performance, and aging in preclinical models.
A practical guide for researchers working with humanin and its potent analog HNG (S14G-humanin), covering reconstitution, dosing strategies, storage requirements, analog selection, and safety considerations.
A comparative analysis of humanin against epithalon and MOTS-c, evaluating their distinct approaches to combating age-related decline through cytoprotection, telomere maintenance, and metabolic regulation respectively.
Humanin is the first mitochondrial-derived peptide, discovered in 2001 in brain tissue from a familial Alzheimer's patient. It protects cells through STAT3, IGFBP-3 and BAX, and circulating levels decline with age; the HNG analog is roughly 1000-fold more potent. No human therapeutic trials have been completed — human evidence is observational, on endogenous levels — and long-term safety data is absent.
Epithalon is a stable tetrapeptide of roughly 390 daltons supplied in 5 mg or 10 mg vials. Research protocols use 5 to 10 mg per day subcutaneously for 10 to 20 days, or 0.5 mg sublingually over a 20-day course, followed by 4 to 6 months off. Its main limitation is the absence of large-scale Western clinical trial data.
A comparative analysis of epithalon against humanin and MOTS-c, examining how these three longevity peptides target different hallmarks of aging through distinct mechanisms including telomerase activation, cytoprotection, and metabolic optimization.
A thorough review of epithalon (epitalon), the synthetic tetrapeptide developed by Vladimir Khavinson that activates telomerase to elongate telomeres, restore pineal gland melatonin production, and extend lifespan in preclinical models.
A practical guide to bone broth peptides covering preparation methods for consistent composition, analytical characterization approaches, supplementation protocols, heavy metal safety testing, and considerations for using bone broth in clinical research settings.
A comparative evaluation of bone broth peptides against purified collagen peptides and marine collagen, examining trade-offs between compositional complexity and standardization, clinical evidence, and practical considerations for different health applications.
A comprehensive review of bone broth peptides as collagen-derived bioactive compounds, covering their complex composition of amino acids, glycosaminoglycans, and minerals, alongside emerging research on gut health, joint support, and anti-inflammatory properties.
A practical guide to Syn-Ake covering formulation concentrations, application protocols from clinical trials, in vitro muscle contraction assay methodology, stability parameters, and combination strategies with complementary anti-wrinkle peptides.
A comparative analysis of Syn-Ake and Argireline as the two leading neuromuscular-targeting cosmetic peptides, examining their distinct receptor-level mechanisms, clinical efficacy data, and potential for synergistic combination.
A comprehensive review of Syn-Ake (dipeptide diaminobutyroyl benzylamide diacetate), the synthetic venom-inspired peptide developed by Pentapharm, covering its nicotinic receptor antagonism mechanism and clinical evidence for expression wrinkle reduction.
A practical guide to afamelanotide covering the approved clinical administration protocol, research dosing in investigational studies, melanin measurement methodologies, storage requirements, and regulatory considerations for clinical investigation.
A unique comparative analysis of Melanotan I as an MC1R-selective tanning peptide, examining its distinct position relative to Melanotan II, natural UV tanning, and topical DHA-based self-tanners as approaches to skin darkening and photoprotection.
A comprehensive review of Melanotan I (afamelanotide), the synthetic alpha-MSH analog developed at the University of Arizona, covering its MC1R-selective mechanism, FDA approval for erythropoietic protoporphyria, and investigational photoprotective applications.
A practical guide to Matrixyl covering formulation approaches, concentration optimization, delivery vehicle selection, stability considerations, in vitro testing protocols, and integration with other cosmetic actives.
A comparative analysis of Matrixyl with GHK-Cu and Argireline, examining the distinct mechanisms by which these cosmetic peptides address skin aging through matrix stimulation, gene modulation, and neuromuscular approaches respectively.
A thorough examination of Matrixyl (palmitoyl pentapeptide-4), the procollagen fragment-based cosmetic peptide developed by Sederma, covering its matrikine mechanism, clinical evidence for wrinkle reduction, and the evolution to Matrixyl 3000.
A practical guide to marine collagen covering sourcing considerations, hydrolysis parameters, quality assessment, supplementation protocols from published studies, storage requirements, and allergen safety management.
A head-to-head comparison of marine collagen with bovine collagen peptides and bone broth peptides, evaluating differences in collagen type profiles, molecular characteristics, bioavailability, sustainability, and application-specific evidence.
A detailed review of marine collagen peptides derived from fish and aquatic sources, covering their Type I collagen composition, superior bioavailability characteristics, and growing clinical evidence for skin health, wound healing, and antioxidant effects.
A practical guide to collagen peptide supplementation covering evidence-based dosing protocols, optimal timing and combinations, quality assessment criteria, storage requirements, and considerations for different health applications.
A comparative evaluation of bovine collagen peptides, marine collagen, and bone broth peptides, examining differences in source material, collagen type composition, molecular weight, bioavailability, and clinical evidence.
A comprehensive review of hydrolyzed collagen peptides covering the major collagen types, enzymatic hydrolysis processes, bioavailability mechanisms, and clinical evidence for benefits in skin health, joint function, and bone density.
A practical guide to Argireline covering formulation concentrations, application protocols from clinical studies, compatibility considerations, storage guidelines, and safety parameters for topical cosmeceutical research.
A comparative analysis of Argireline against other neuromuscular-targeting cosmetic peptides including Syn-Ake and Matrixyl, evaluating their distinct mechanisms at the neuromuscular junction and relative clinical performance.
An in-depth review of Argireline (acetyl hexapeptide-8), the SNAP-25 mimetic peptide developed by Lipotec, exploring its neuromuscular mechanism, clinical wrinkle reduction data, and positioning as a topical alternative to botulinum toxin.
A practical guide to GHK-Cu covering topical and injectable formulation approaches, concentration guidelines derived from published research, reconstitution protocols, storage requirements, and safety considerations for investigational use.
A detailed comparison of GHK-Cu with other cosmetic peptides including Argireline and Matrixyl, examining their distinct mechanisms of action, clinical evidence, and relative efficacy in anti-aging skin care applications.
A thorough examination of GHK-Cu, the naturally occurring copper-binding tripeptide discovered in human plasma, covering its molecular biology, gene-modulating mechanisms, and extensive research on wound healing, skin remodeling, and anti-aging applications.
A detailed comparison of various growth hormone secretagogues including GHRP-6, GHRP-2, Ipamorelin, and CJC-1295. Analyzes efficacy, side effect profiles, and optimal usage protocols.
Essential information on maintaining peptide stability through proper storage conditions, reconstitution techniques, and handling procedures. Covers lyophilized and reconstituted peptide storage.
A comprehensive review of BPC-157's tissue repair mechanisms, including angiogenesis promotion, collagen production, and cellular migration enhancement. This study examines the peptide's role in healing various tissue types.
Copper Tripeptide-1 (GHK-Cu) is the blue-tinted copper complex behind many peptide creams and serums. Its collagen-stimulating effect was shown in fibroblast cultures in 1988, and a 2007 in vitro study reported follicle growth; human skin data remain small, short and industry-connected, with no head-to-head trials against retinoids. Injectable GHK-Cu is a separate, unapproved research substance.
Selank and Semax are Russian heptapeptides sharing a Pro-Gly-Pro tail but differing in origin: tuftsin for Selank, an ACTH(4-7) fragment for Semax. Selank was studied for anxiety disorder against medazepam (62 patients), Semax for acute ischaemic stroke. Selank has one strength, 0.15%; Semax two, 0.1% and 1%. Both are approved in Russia only; neither reviewed by the FDA or EMA.
In July 2026 the FDA's Pharmacy Compounding Advisory Committee recommended six of seven nominated peptides — BPC-157, KPV, TB-500, MOTS-c, Semax and Epitalon — for the 503A Bulks List and rejected Emideltide (DSIP) 6–7, overruling the agency's own reviewers. The vote is non-binding: the list changes only through rulemaking that had not begun, and no peptide's research status changed.
Before you compare peptides, it is worth understanding where the statuses and numbers in their profiles come from. This explainer shows how to tell preclinical evidence from clinical, read dosages without illusions, and spot the line where science ends and marketing begins.
Discover our comprehensive peptide database, protocols, and research tools.